Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
Ocugen signed a binding term sheet with Roots Pharmaceutical and Al-Dhow International Holding for the exclusive license of OCU400 in the Middle East and North Africa region. The agreement terms include upfront and near-term milestones totaling up to $4 million, sales milestones up to $255 million, and a 22% royalty on net sales; Ocugen will retain manufacturing rights.
Key figures
- Drug Name
- OCU400
- Deal Value Usd
- 255000000
- Phase Of Trial
- Phase 3
- Royalty rate
- 22%
- Upfront milestones
- $4 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.